These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 16900637)
81. Fractal dimension as a quantitator of the microvasculature of normal and adenomatous pituitary tissue. Di Ieva A; Grizzi F; Ceva-Grimaldi G; Russo C; Gaetani P; Aimar E; Levi D; Pisano P; Tancioni F; Nicola G; Tschabitscher M; Dioguardi N; Baena RR J Anat; 2007 Nov; 211(5):673-80. PubMed ID: 17784937 [TBL] [Abstract][Full Text] [Related]
82. Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators. Giaginis C; Tsantili-Kakoulidou A; Theocharis S Expert Opin Investig Drugs; 2007 Feb; 16(2):195-207. PubMed ID: 17243939 [TBL] [Abstract][Full Text] [Related]
83. Peroxisome Proliferator-Activated Receptor-gamma Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular Cancer. Matsuyama M; Yoshimura R PPAR Res; 2008; 2008():249849. PubMed ID: 18317513 [TBL] [Abstract][Full Text] [Related]
84. Bacterial expression, refolding, functional characterization, and mass spectrometric identification of full-length human PPAR-gamma. Li W; Yuan Y; Luo Z; Zheng X; Zhao L; Duan W; Yu Y Biosci Biotechnol Biochem; 2010; 74(6):1173-80. PubMed ID: 20530906 [TBL] [Abstract][Full Text] [Related]
85. Response to Letter to the Editor: "Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas". Lim JS; Lee EJ Endocrine; 2019 May; 64(2):428-429. PubMed ID: 31020462 [No Abstract] [Full Text] [Related]
86. Wnt signalling in pituitary development and tumorigenesis. Chambers TJ; Giles A; Brabant G; Davis JR Endocr Relat Cancer; 2013 Jun; 20(3):R101-11. PubMed ID: 23689382 [TBL] [Abstract][Full Text] [Related]
87. [The expression and significance of peroxisome proliferator-activated receptor-gamma in airway remodeling of asthmatic rats]. Wang XF; Qiao JY; Luan B; Jia T; Zou L; Feng J Zhonghua Er Ke Za Zhi; 2004 Dec; 42(12):946-7. PubMed ID: 15733374 [No Abstract] [Full Text] [Related]
89. Vascular lesions in pituitary adenomas. LIST CF; WILLIAMS JR; BALYEART GW J Neurosurg; 1952 Mar; 9(2):177-87. PubMed ID: 14908652 [No Abstract] [Full Text] [Related]
90. Experience with surgical treatment in twenty cases of pituitary adenomas. ECHOLS DH J Neurosurg; 1958 Jul; 15(4):447-54. PubMed ID: 13564271 [No Abstract] [Full Text] [Related]
91. Roentgen therapy of pituitary adenomas. MUFSON JA; BLANKSTEIN SS Wis Med J; 1946 Jul; 45():680-5. PubMed ID: 20990224 [No Abstract] [Full Text] [Related]
92. Correlation of NEDD4-1 and PTEN expression with the invasive capacity of pituitary adenomas. Zhang J; Li X; Zhang Y Mol Clin Oncol; 2017 Jan; 6(1):96-100. PubMed ID: 28123738 [TBL] [Abstract][Full Text] [Related]
93. [The role and mechanism of peroxisome proliferator-activated receptor γ in the pathogenesis of atherosclerotic vulnerable plaque]. Qin C; Li H Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Mar; 42(3):266-8. PubMed ID: 24831490 [No Abstract] [Full Text] [Related]
94. Adenomas of the pituitary gland. BAGCHI A J Indian Med Assoc; 1961 May; 36():439-47. PubMed ID: 13685841 [No Abstract] [Full Text] [Related]
95. [To strengthen the protection of the residual pituitary function in the course of the treatment of pituitary adenomas]. Feng M; Wang RZ Zhonghua Yi Xue Za Zhi; 2012 Oct; 92(39):2737-8. PubMed ID: 23290157 [No Abstract] [Full Text] [Related]